130 related articles for article (PubMed ID: 31473819)
1. Antiangiogenic therapy with Nintedanib affects hypoxia, angiogenesis and apoptosis in the ventral prostate of TRAMP animals.
da Silva RF; Banzato TP; Alves LF; Carvalho JE; Agarwal R; Cagnon VHA
Cell Tissue Res; 2020 Feb; 379(2):407-420. PubMed ID: 31473819
[TBL] [Abstract][Full Text] [Related]
2. Nintedanib antiangiogenic inhibitor effectiveness in delaying adenocarcinoma progression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP).
da Silva RF; Nogueira-Pangrazi E; Kido LA; Montico F; Arana S; Kumar D; Raina K; Agarwal R; Cagnon VHA
J Biomed Sci; 2017 May; 24(1):31. PubMed ID: 28499383
[TBL] [Abstract][Full Text] [Related]
3. Association of anti-inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice.
Mateus PAM; Kido LA; Silva RS; Cagnon VHA; Montico F
Prostate; 2019 Apr; 79(5):515-535. PubMed ID: 30585351
[TBL] [Abstract][Full Text] [Related]
4. Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Montico F; Kido LA; Hetzl AC; Cagnon VH
Prostate; 2015 Apr; 75(5):484-99. PubMed ID: 25521760
[TBL] [Abstract][Full Text] [Related]
5. Nintedanib treatment delays prostate dorsolateral lobe cancer progression in the TRAMP model: contribution to the epithelial-stromal interaction balance.
Nogueira Pangrazi E; da Silva RF; Kido LA; Montico F; Cagnon VHA
Cell Biol Int; 2018 Feb; 42(2):153-168. PubMed ID: 28980742
[TBL] [Abstract][Full Text] [Related]
6. SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis.
Huss WJ; Barrios RJ; Greenberg NM
Mol Cancer Ther; 2003 Jul; 2(7):611-6. PubMed ID: 12883033
[TBL] [Abstract][Full Text] [Related]
7. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model.
Raina K; Rajamanickam S; Singh RP; Deep G; Chittezhath M; Agarwal R
Cancer Res; 2008 Aug; 68(16):6822-30. PubMed ID: 18701508
[TBL] [Abstract][Full Text] [Related]
8. Augmentation of
Awasthi N; Schwarz MA; Zhang C; Schwarz RE
Mol Cancer Ther; 2018 Nov; 17(11):2353-2364. PubMed ID: 30166402
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis and prostate cancer: identification of a molecular progression switch.
Huss WJ; Hanrahan CF; Barrios RJ; Simons JW; Greenberg NM
Cancer Res; 2001 Mar; 61(6):2736-43. PubMed ID: 11289156
[TBL] [Abstract][Full Text] [Related]
10. Nintedanib effects on delaying cancer progression and decreasing COX-2 and IL-17 in the prostate anterior lobe in TRAMP mice.
Alves LF; da Silva RF; Cagnon VHA
Tissue Cell; 2018 Feb; 50():96-103. PubMed ID: 29429524
[TBL] [Abstract][Full Text] [Related]
11. Lobe-specific responses of TRAMP mice dorsolateral prostate following celecoxib and nintedanib therapy.
Montico F; Lamas CA; Rossetto IMU; Baseggio AM; Cagnon VHA
J Mol Histol; 2023 Aug; 54(4):379-403. PubMed ID: 37335420
[TBL] [Abstract][Full Text] [Related]
12. Apigenin attenuates insulin-like growth factor-I signaling in an autochthonous mouse prostate cancer model.
Shukla S; MacLennan GT; Fu P; Gupta S
Pharm Res; 2012 Jun; 29(6):1506-17. PubMed ID: 22139534
[TBL] [Abstract][Full Text] [Related]
13. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice.
Singh RP; Raina K; Sharma G; Agarwal R
Clin Cancer Res; 2008 Dec; 14(23):7773-80. PubMed ID: 19047104
[TBL] [Abstract][Full Text] [Related]
14. Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases.
Hilberg F; Tontsch-Grunt U; Baum A; Le AT; Doebele RC; Lieb S; Gianni D; Voss T; Garin-Chesa P; Haslinger C; Kraut N
J Pharmacol Exp Ther; 2018 Mar; 364(3):494-503. PubMed ID: 29263244
[TBL] [Abstract][Full Text] [Related]
15. Nintedanib inhibits growth of human prostate carcinoma cells by modulating both cell cycle and angiogenesis regulators.
da Silva RF; Dhar D; Raina K; Kumar D; Kant R; Cagnon VHA; Agarwal C; Agarwal R
Sci Rep; 2018 Jun; 8(1):9540. PubMed ID: 29934570
[TBL] [Abstract][Full Text] [Related]
16. Reactive stroma in the prostate during late life: The role of microvasculature and antiangiogenic therapy influences.
Montico F; Kido LA; San Martin R; Rowley DR; Cagnon VH
Prostate; 2015 Oct; 75(14):1643-61. PubMed ID: 26184673
[TBL] [Abstract][Full Text] [Related]
17. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.
Hostettler KE; Zhong J; Papakonstantinou E; Karakiulakis G; Tamm M; Seidel P; Sun Q; Mandal J; Lardinois D; Lambers C; Roth M
Respir Res; 2014 Dec; 15(1):157. PubMed ID: 25496490
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis.
Bono AV; Pannellini T; Liberatore M; Montironi R; Cunico SC; Cheng L; Sasso F; Musiani P; Iezzi M
Anal Quant Cytol Histol; 2010 Jun; 32(3):136-45. PubMed ID: 20701066
[TBL] [Abstract][Full Text] [Related]
19. Nintedanib Is a Highly Effective Therapeutic for Neuroendocrine Carcinoma of the Pancreas (PNET) in the Rip1Tag2 Transgenic Mouse Model.
Bill R; Fagiani E; Zumsteg A; Antoniadis H; Johansson D; Haefliger S; Albrecht I; Hilberg F; Christofori G
Clin Cancer Res; 2015 Nov; 21(21):4856-67. PubMed ID: 26206868
[TBL] [Abstract][Full Text] [Related]
20. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
